Ovid Therapeutics (OVID) EBITDA (2016 - 2026)

Ovid Therapeutics has reported EBITDA for 11 years, with the latest figure at -$17.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 42.2% year-over-year to -$17.8 million; the trailing twelve-month figure through Mar 2026 stood at -$47.7 million (up 16.28% YoY), and the FY2025 full-year result was -$42.4 million, up 31.42% from the prior year.
• EBITDA for Q1 2026 stood at -$17.8 million, down from -$12.3 million in the prior quarter.
• The five-year high for EBITDA was -$5.1 million in Q2 2025, with the low at -$20.5 million in Q2 2024.
• Historically, EBITDA has averaged -$13.9 million across 5 years, with a median of -$13.2 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA sank 109.21% — and 2025, when it jumped 75.27%.
• Ovid Therapeutics' EBITDA stood at -$12.2 million in 2022, then tumbled by 49.41% to -$18.2 million in 2023, then soared by 41.05% to -$10.7 million in 2024, then retreated by 14.65% to -$12.3 million in 2025, then sank by 45.17% to -$17.8 million in 2026.
• The last three EBITDA figures came in at -$17.8 million (Q1 2026), -$12.3 million (Q4 2025), and -$12.5 million (Q3 2025), per Business Quant data.